Aberrant kinetics of bone marrow-derived endothelial progenitor cells in the murine oxygen-induced retinopathy model

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 11, 2011, Pages 7835-7841

  Nakagawa, Yoshihiro ^a   Masuda, Haruchika ^a   Ito, Rie ^a   Kobori, Michiru ^a   Wada, Mika ^a   Shizuno, Tomoko ^a   Sato, Atsuko ^a   Suzuki, Takahiro ^a   Kawai, Kenji ^a   Asahara, Takayuki ^a,b,c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

^c INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; COLONY FORMING CELL; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FLUORESCENCE ACTIVATED CELL SORTING; HYPOXIA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINOPATHY;

ANIMALS; ANIMALS, NEWBORN; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT, NEWBORN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; OXYGEN; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053635207     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5880     Document Type: Article

References (48)

1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS. 1999;3:26-32.
2. Patz A. The role of oxygen in retrolental fibroplasia. Trans Am Ophthalmol Soc. 1968;66:940-985.
3. Flower RW, McLeod DS, Lutty GA, Goldberg B, Wajer SD. Postnatal retinal vascular development of the puppy. Invest Ophthalmol Vis Sci. 1985;26:957-968.
4. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthal-mol Vis Sci. 1993;34:576-585.
5. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced reti-nopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
6. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009; 4:1565-1573.
7. Banin E, Dorrell MI, Aguilar E, et al. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006;47:2125-2134.
8. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neo-natol. 2003;8:469-473.
9. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007; 10:133-140.
10. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
11. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res. 1996;15:175-184.
12. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-1228.
13. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoi-etin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:393-402.
14. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 1999;40:182-189.
15. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endo-thelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390-1395.
16. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
17. Stitt AW, Graham D, Gardiner TA. Ocular wounding prevents pre-retinal neovascularization and upregulates PEDF expression in the inner retina. Mol Vis. 2004;10:432-438.
18. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopa-thy. Exp Eye Res. 2004;79:623-630.
19. Maeng YS, Choi HJ, Kwon JY, et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. Blood. 2009;113:233-243.
20. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
21. Masuda H, Kalka C, Takahashi T, et al. Estrogen-mediated endo-thelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res. 2007;101:598-606.
22. Otani A, Dorrell MI, Kinder K, et al. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest. 2004;114:765-774.
23. Dorrell MI, Otani A, Aguilar E, Moreno SK, Friedlander M. Adult bone marrow-derived stem cells use R-cadherin to target sites of neovascularization in the developing retina. Blood. 2004;103: 3420-3427.
24. Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neo-vascularization. Nat Med. 2002;8:607-612.
25. Yodoi Y, Sasahara M, Kameda T, Yoshimura N, Otani A. Circulating hematopoietic stem cells in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:5464-5472.
26. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia. 2006;49:3075-3084.
27. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407:313-319.
28. Hisatomi T, Sonoda KH, Ishikawa F, et al. Identification of resident and inflammatory bone marrow derived cells in the sclera by bone marrow and haematopoietic stem cell transplantation. Br J Oph-thalmol. 2007;91:520-526.
29. Tamaki T, Uchiyama Y, Okada Y, et al. Functional recovery of damaged skeletal muscle through synchronized vasculogenesis, myogenesis, and neurogenesis by muscle-derived stem cells. Circulation. 2005;2857-2866.
30. Kwon SM, Suzuki T, Kawamoto A, et al. Pivotal role of link adaptor protein in endothelial progenitor cell biology for vascular regeneration. Circ Res. 2009;104:969-977.
31. Tanaka R, Wada M, Kwon SM, et al. The effects of flap ischemia on normal and diabetic progenitor cell function. Plast Reconstr Surg. 2008;121:1929-1942.
32. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002;8:1004-1010.
33. Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:4908-4913.
34. Sengupta N, Caballero S, Mames RN, Timmers AM, Saban D, Grant MB. Preventing stem cell incorporation into choroidal neovascu-larization by targeting homing and attachment factors. Invest Oph-thalmol Vis Sci. 2005;46:343-348.
35. Tomita M, Yamada H, Adachi Y, et al. Choroidal neovascularization is provided by bone marrow cells. Stem Cells. 2004;22:21-26.
36. Takahashi H, Yanagi Y, Tamaki Y, Muranaka K, Usui T, Sata M. Contribution of bone-marrow-derived cells to choroidal neovascu-larization. Biochem Biophys Res Commun. 2004;320:372-375.
37. Chang KH, Chan-Ling T, McFarland EL, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA. 2007;104:10595-10600.
38. Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinop-athy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA. 2007;104: 10589-10594.
39. Machalinska A, Modrzejewska M, Kotowski M, et al. Circulating stem cell populations in preterm infants: implications for the development of retinopathy of prematurity. Arch Ophthalmol. 128:1311-1319.
40. Yang J, Ii M, Kamei N, et al. CD34 cells represent highly functional endothelial progenitor cells in murine bone marrow. PLoS One. 2011;6:e20219.
41. Masuda H, Alev C, Akimaru H, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res. 2011;109:20-37.
42. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-1694.
43. Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol. 2006;142:636-643.
44. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161-1163.
45. Zamora DO, Davies MH, Planck SR, Rosenbaum JT, Powers MR. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascular-ization in a model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2175-2182.
46. Spandau UH, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol. 2005;89:745-747.
47. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450-1455.
48. Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R, Far-zavandi S. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. Trans Am Oph-thalmol Soc. 2006;104:78-84.